These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26957641)

  • 1. Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.
    Ellis SD; Chen RC; Dusetzina SB; Wheeler SB; Jackson GL; Nielsen ME; Carpenter WR; Weinberger M
    J Oncol Pract; 2016 Apr; 12(4):e423-36. PubMed ID: 26957641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.
    Ellis SD; Nielsen ME; Carpenter WR; Jackson GL; Wheeler SB; Liu H; Weinberger M
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):173-81. PubMed ID: 25849354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.
    Chang SL; Liao JC; Shinghal R
    J Urol; 2009 Jul; 182(1):255-60; discussion 261. PubMed ID: 19450844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
    Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
    Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Weight CJ; Klein EA; Jones JS
    Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Reimbursement: From Fee-for-Service to MACRA, MIPS and APMs.
    Miller P; Mosley K
    J Med Pract Manage; 2016; 31(5):266-9. PubMed ID: 27249873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
    Shahinian VB; Kuo YF; Gilbert SM
    N Engl J Med; 2010 Nov; 363(19):1822-32. PubMed ID: 21047226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare fees and the volume of physicians' services.
    Hadley J; Reschovsky J; Corey C; Zuckerman S
    Inquiry; 2009-2010 Winter; 46(4):372-90. PubMed ID: 20184165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender Differences in Physician Service Provision Using Medicare Claims Data.
    Mahr MA; Hayes SN; Shanafelt TD; Sloan JA; Erie JC
    Mayo Clin Proc; 2017 Jun; 92(6):870-880. PubMed ID: 28501293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
    Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
    Cancer; 2005 Apr; 103(8):1615-24. PubMed ID: 15742331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans.
    Riley GF; Warren JL; Potosky AL; Klabunde CN; Harlan LC; Osswald MB
    Med Care; 2008 Oct; 46(10):1108-15. PubMed ID: 18815533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adequacy of physician reimbursement for pediatric care under Medicaid.
    McManus M; Flint S; Kelly R
    Pediatrics; 1991 Jun; 87(6):909-20. PubMed ID: 2034498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
    Shahinian VB; Kuo YF
    BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Area-level variations in cancer care and outcomes.
    Keating NL; Landrum MB; Lamont EB; Bozeman SR; McNeil BJ
    Med Care; 2012 May; 50(5):366-73. PubMed ID: 22437623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States.
    Cetin K; Li S; Blaes AH; Stryker S; Liede A; Arneson TJ
    Urology; 2013 Jun; 81(6):1184-9. PubMed ID: 23601449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer.
    Gross CP; Andersen MS; Krumholz HM; McAvay GJ; Proctor D; Tinetti ME
    JAMA; 2006 Dec; 296(23):2815-22. PubMed ID: 17179458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice arrangement and medicare physician payment in otolaryngology.
    Cracchiolo J; Ridge JA; Egleston B; Lango M
    Otolaryngol Head Neck Surg; 2015 Jun; 152(6):979-87. PubMed ID: 26034098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician payment outlook for 2012: déjà vu.
    Manchikanti L; Singh V; Caraway DL; Benyamin RM; Falco FJ; Hirsch JA
    Pain Physician; 2012; 15(1):E27-52. PubMed ID: 22270747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.